PT  - JOURNAL ARTICLE
AU  - Takuo Yoshimoto
AU  - Takayuki Furuki
AU  - Hiroyuki Kobori
AU  - Masaaki Miyakawa
AU  - Hitomi Imachi
AU  - Koji Murao
AU  - Akira Nishiyama
TI  - Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
AID  - 10.1136/jim-2017-000445
DP  - 2017 Oct 01
TA  - Journal of Investigative Medicine
PG  - 1057--1061
VI  - 65
IP  - 7
4099  - http://hw-f5-jim.highwire.org/content/65/7/1057.short
4100  - http://hw-f5-jim.highwire.org/content/65/7/1057.full
SO  - J Investig Med2017 Oct 01; 65
AB  - We conducted a descriptive case study to examine the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function of the intrarenal renin–angiotensin system, in patients with type 2 diabetes. An SGLT2 inhibitor (canagliflozin 100 mg/day, ipragliflozin 25 mg/day, dapagliflozin 5 mg/day, luseogliflozin 2.5 mg/day or tofogliflozin 20 mg/day) was administered for 1 month (n=9). ELISA kits were used to measure both urinary intact and total angiotensinogen levels. Treatment with SGLT2 inhibitors significantly decreased hemoglobin A1c, body weight, systolic blood pressure and diastolic blood pressure (8.5±1.3 to 7.5%±1.0%, 82.5±20.2 to 80.6±20.9 kg, 143±8 to 128±14 mm Hg, 78±10 to 67±9 mm Hg, p<0.05, respectively), while urinary albumin/creatinine ratio was not significantly changed (58.6±58.9 to 29.2±60.7 mg/g, p=0.16). Both total urinary angiotensinogen/creatinine ratio and intact urinary angiotensinogen/creatinine ratio tended to decrease after administration of SGLT2 inhibitors. However, these changes were not significant (p=0.19 and p=0.08, respectively). These data suggest that treatment with SGLT2 inhibitors does not activate the intrarenal renin–angiotensin system in patients with type 2 diabetes.